IL-37 Mitigates the Inflammatory Response in Macrophages Induced by SARS-CoV-2 Omicron Infection Through the NF-κB Signaling Pathway

Abstract

The expression levels of macrophage-associated cytokines are significantly greater in COVID-19 patients than in healthy individuals. Exploring strategies to modulate pathological cytokine storms can effectively prevent the development of severe coronavirus infection-induced pneumonia. Treatment with interleukin-37 (IL-37), an anti-inflammatory factor, has unique anti-inflammatory and antiviral effects on infections caused by various pathogens. In this study, we investigated the effect of IL-37 treatment on the SARS-CoV-2 Omicron-infection induced inflammatory response and its molecular mechanism. Our results demonstrated that IL-37 treatment effectively alleviated symptoms, reduced viral loads, suppressed the production of proinflammatory cytokines and chemokines both systemically (in serum) and locally (in the lungs), and attenuated lung lesions and inflammatory cell infiltration in Omicron-infected mice. The suppressed proinflammatory factors were macrophage-related, particularly CCL3 and CCL4, which were significantly inhibited. Furthermore, treatment with IL-37 significantly reduced the proportion of M1-type macrophages in lungs of Omicron-infected mice. In addition, we found that IL-37 targeted M1 macrophages through modulation of the NF-κB signaling pathway to suppress the production of proinflammtory factors during Omicron infection. This study elucidated the anti-inflammatory effect of IL-37 treatment on the Omicron-induced inflammatory response while identifying its specific target site, thereby providing fundamental insights for exploring potential clinical therapeutic interventions.

Keywords

IL-37 / inflammatory response / macrophages / NF-κB / omicron

References

[1] X. Lei, X. Dong, R. Ma, et al., “Activation and Evasion of Type I Interferon Responses by SARS-CoV-2,” Nature Communications 11, no. 1 (2020): 3810.

[2] D. Blanco-Melo, B. E. Nilsson-Payant, W. C. Liu, et al., “Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19,” Cell 181, no. 5 (2020): 1036-1045.

[3] C. Huang, Y. Wang, X. Li, et al., “Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China,” Lancet 395, no. 10223 (2020): 497-506.

[4] F. Zhang, J. R. Mears, L. Shakib, et al., “IFN-γ and TNF-α Drive a CXCL10+ CCL2+ Macrophage Phenotype Expanded in Severe COVID-19 Lungs and Inflammatory Diseases With Tissue Inflammation,” Genome Medicine 13, no. 1 (2021): 64.

[5] S. W. Yin, Z. Zhou, J. L. Wang, et al., “Viral Loads, Lymphocyte Subsets and Cytokines in Asymptomatic, Mildly and Critical Symptomatic Patients With SARS-CoV-2 Infection: A Retrospective Study,” Virology Journal 18, no. 1 (2021): 126.

[6] C. Y. Cheung, L. L. Poon, I. H. Ng, et al., “Cytokine Responses in Severe Acute respiratory Syndrome Coronavirus-Infected Macrophages in Vitro: Possible Relevance to Pathogenesis,” Journal of Virology 79, no. 12 (2005): 7819-7826.

[7] H. K. Law, C. Y. Cheung, H. Y. Ng, et al., “Chemokine Up-Regulation in SARS-Coronavirus-Infected, Monocyte-Derived Human Dendritic Cells,” Blood 106, no. 7 (2005): 2366-2374.

[8] K. O. Alsaad, A. H. Hajeer, M. Al Balwi, et al., “Histopathology of Middle East respiratory Syndrome Coronovirus (MERS-CoV) Infection-Clinicopathological and Ultrastructural Study,” Histopathology 72, no. 3 (2018): 516-524.

[9] Y. Feng, L. Hu, S. Lu, et al., “Molecular Pathology Analyses of Two Fatal Human Infections of Avian Influenza A(H7N9) Virus,” Journal of Clinical Pathology 68, no. 1 (2015): 57-63.

[10] S. Fishbane, J. S. Hirsch, and V. Nair, “Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection,” American Journal of Kidney Diseases 79, no. 4 (2022): 480-482.

[11] Y. Wang, D. Zhang, G. Du, et al., “Remdesivir in Adults With Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial,” Lancet 395, no. 10236 (2020): 1569-1578.

[12] J. H. Chow, A. Rahnavard, M. Gomberg-Maitland, et al., “Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19,” JAMA Network Open 5, no. 3 (2022): e223890.

[13] A. Sahai, R. Bhandari, M. Godwin, et al., “Effect of Aspirin on Short-Term Outcomes in Hospitalized Patients With COVID-19,” Vascular Medicine 26, no. 6 (2021): 626-632.

[14] J. Peng, X. She, H. Mei, et al., “Association Between Tocilizumab Treatment and Clinical Outcomes of COVID-19 Patients: A Systematic Review and Meta-Analysis,” Aging (Albany NY) 14, no. 2 (2022): 557-571.

[15] Y. Xu, J. Y. Wang, Y. Zou, et al., “Role of IL-1 Family Cytokines IL-36, IL-37, IL-38 in Osteoarthritis and Rheumatoid Arthritis: A Comprehensive Review,” Journal of Inflammation Research 17 (2024): 4001-4016.

[16] M. Gu, Y. Jin, and X. Gao, S. Pan, “Novel Insights Into IL-37: An Anti-Inflammatory Cytokine With Emerging Roles in Anti-Cancer Process,” Frontiers in Immunology 14 (2023): 1278521.

[17] F. Zhou, C. L. Zhu, Z. L. Niu, et al., “Influenza A Virus Inhibits Influenza Virus Replication by Inducing IL-37,” Journal of Clinical Laboratory Analysis 33, no. 1 (2019): e22638.

[18] F. Qi, M. Liu, F. Li, et al., “Interleukin-37 Ameliorates Influenza Pneumonia by Attenuating Macrophage Cytokine Production in a MAPK-Dependent Manner,” Frontiers in Microbiology 10 (2019): 2482.

[19] L. Sun, H. Yuan, and G. Zhao, “IL-37 Alleviates Coxsackievirus B3-Induced Viral Myocarditis via Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis,” Scientific Reports 12, no. 1 (2022): 20077.

[20] Y. Ruan, Z. Wen, K. Chen, et al., “Exogenous Interleukin-37 Alleviates Hepatitis With Reduced Dendritic Cells and Induced Regulatory T Cells in Acute Murine Cytomegalovirus Infection,” Journal of Immunology Research 2023 (2023): 1462048.

[21] F. Qi, Y. Yan, Q. Lv, et al., “IL-37 Possesses Both Anti-Inflammatory and Antiviral Effects Against Middle East Respiratory Syndrome Coronavirus Infection,” Animal Models and Experimental Medicine 8, no. 3 (2025): 483-492.

[22] S. Li, J. Amo-Aparicio, C. P. Neff, et al., “Role for Nuclear Interleukin-37 in the Suppression of Innate Immunity,” PNAS 116, no. 10 (2019): 4456-4461.

[23] A. Li, Y. Ling, Z. Song, et al., “Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection,” Journal of Infectious Diseases 223, no. 4 (2021): 568-580.

[24] R. A. Grant, L. Morales-Nebreda, N. S. Markov, et al., “Circuits Between Infected Macrophages and T Cells in SARS-CoV-2 Pneumonia,” Nature 590, no. 7847 (2021): 635-641.

[25] B. Han, Y. Lv, D. Moser, et al., “ACE2-Independent SARS-CoV-2 Virus Entry Through Cell Surface GRP78 on Monocytes—Evidence From a Translational Clinical and Experimental Approach,” EBioMedicine 98 (2023): 104869.

[26] D. Wendisch, O. Dietrich, T. Mari, et al., “SARS-CoV-2 Infection Triggers Profibrotic Macrophage Responses and Lung Fibrosis,” Cell 184, no. 26 (2021): 6243-6261.

[27] H. Ding, S. Wu, X. Dai, et al., “Pharmacokinetic Behavior of Peramivir in the Plasma and Lungs of Rats After Trans-Nasal Aerosol Inhalation and Intravenous Injection,” Biomedicine & Pharmacotherapy 129 (2020): 110464.

[28] Q. Lu, C. Girardi, M. Zhang, et al., “Nebulized and Intravenous Colistin in Experimental Pneumonia Caused by Pseudomonas aeruginosa,” Intensive Care Medicine 36, no. 7 (2010): 1147-1155.

[29] M. S. Piepenbrink, J. G. Park, F. S. Oladunni, et al., “Therapeutic Activity of an Inhaled Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody in Hamsters,” Cell Reports Medicine 2, no. 3 (2021): 100218.

[30] G. Zhang, Y. Li, T. Chen, et al., “Comparative Study of the Efficacy and Pharmacokinetics of Reduning Injection and Atomization Inhalation,” Biomedicine & Pharmacotherapy 118 (2019): 109226.

[31] J. Lv, Z. Wang, Y. Qu, et al., “Distinct Uptake, Amplification, and Release of SARS-CoV-2 by M1 and M2 Alveolar Macrophages,” Cell Discovery 7, no. 1 (2021): 24.

[32] Y. M. Wang, J. J. Zhang, B. W. Wu, et al., “IL-37 Improves Mice Myocardial Infarction via Inhibiting YAP-NLRP3 Signaling Mediated Macrophage Programming,” European Journal of Pharmacology 934 (2022): 175293.

[33] T. Wu, K. Xu, C. Liu, et al., “Interleukin-37 Ameliorates Cigarette Smoke-Induced Lung Inflammation in Mice,” Biomedicine & Pharmacotherapy 155 (2022): 113684.

[34] R. Kircheis, E. Haasbach, D. Lueftenegger, et al., “NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients,” Frontiers in Immunology 11 (2020): 598444.

[35] S. Khan, M. S. Shafiei, C. Longoria, et al., “SARS-CoV-2 Spike Protein Induces Inflammation via TLR2-Dependent Activation of the NF-κB Pathway,” Elife 10 (2021): e68563.

[36] H. A. Haeberle, R. Takizawa, A. Casola, et al., “Respiratory Syncytial Virus-Induced Activation of Nuclear Factor-kappaB in the Lung Involves Alveolar Macrophages and Toll-Like Receptor 4-Dependent Pathways,” Journal of Infectious Diseases 186, no. 9 (2002): 1199-1206.

[37] W. Wang, L. Ye, L. Ye, et al., “Up-Regulation of IL-6 and TNF-alpha Induced by SARS-Coronavirus Spike Protein in Murine Macrophages via NF-kappaB Pathway,” Virus Research 128, no. 1-2 (2007): 1-8.

[38] Q. Wang, H. Jiang, Y. Li, et al., “Targeting NF-κB Signaling With Polymeric Hybrid Micelles That Co-Deliver siRNA and Dexamethasone for Arthritis Therapy,” Biomaterials 122 (2017): 10-22.

[39] Y. F. Wang, L. N. Zhao, Y. Geng, et al., “Aspirin Modulates Succinylation of PGAM1K99 to Restrict the Glycolysis Through NF-κB/HAT1/PGAM1 Signaling in Liver Cancer,” Acta Pharmacologica Sinica 44, no. 1 (2023): 211-220.

[40] M. L. DeDiego, J. L. Nieto-Torres, J. A. Regla-Nava, et al., “Inhibition of NF-κB-Mediated Inflammation in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice Increases Survival,” Journal of Virology 88, no. 2 (2014): 913-924.

[41] E. Haasbach, S. J. Reiling, C. Ehrhardt, et al., “The NF-kappaB Inhibitor SC75741 Protects Mice Against Highly Pathogenic Avian influenza A Virus,” Antiviral Research 99, no. 3 (2013): 336-344.

[42] Q. Guo, Y. Jin, X. Chen, et al., “NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 53.

[43] M. Li, M. Wang, Y. Wen, et al., “Signaling Pathways in Macrophages: Molecular Mechanisms and Therapeutic Targets,” MedComm 4, no. 5 (2023): e349.

[44] P. Luo, C. Feng, C. Jiang, et al., “IL-37b Alleviates Inflammation in the Temporomandibular Joint Cartilage via IL-1R8 Pathway,” Cell Proliferation 52, no. 6 (2019): e12692.

[45] P. Zhou, Q. Li, S. Su, et al., “Interleukin 37 Suppresses M1 Macrophage Polarization Through Inhibition of the Notch1 and Nuclear Factor Kappa B Pathways,” Frontiers in Cell and Developmental Biology 8 (2020): 56.

[46] L. Bao, W. Deng, B. Huang, et al., “The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice,” Nature 583, no. 7818 (2020): 830-833.

[47] Y. Zhang, Q. Lv, F. Qi, et al., “Comparison of the Replication and Neutralization of Different SARS-CoV-2 Omicron Subvariants in Vitro,” Animal Models and Experimental Medicine 6, no. 1 (2023): 51-56.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.